免疫治疗在EGFR突变非小细胞肺癌中的研究进展

Advances in immunotherapy in EGFR-mutated non-small cell lung cancer

摘要:

表皮生长因子受体酪氨酸激酶（epidermal growth factor receptor，EGFR）驱动基因突变的非小细胞肺癌患者，使用EGFR抑制剂（epidermal growth factor receptor inhibitors，EGFR-TKIs）是标准治疗模式，但获得性耐药不可避免。对于一线EGFR-TKIs耐药的非小细胞肺癌（non-small cell lung cancer，NSCLC）患者，目前没有标准的治疗方式。免疫治疗联合含铂双药化疗、血管内皮生长因子（vascular endothelial growth factor，VEGF）抑制剂的治疗模式显示出了一定的疗效。本文通过综述不同程序性死亡蛋白1（programmed cell death 1，PD-1）/PD-1配体（PD-1 ligand，PD-L1）免疫检查点抑制剂在EGFR突变的NSCLC患者的研究现状，并探讨针对EGFR突变的NSCLC患者更加合适的治疗方式。

Abstract:

In patients with non-small cell lung cancer（NSCLC） with EGFR driver mutation，EGFR-TKIs is the standard treatment but acquired resistance is inevitable. There is currently no standard treatment for first-line EGFR-TKIs-resistant NSCLC patients. Immunotherapy combined with platinum-containing double-drug chemotherapy and vascular endothelial growth factor inhibitors has shown some efficacy. This paper reviews the research on different programmed cell death 1（PD-1）/PD-1 ligand（PD-L1） immune checkpoint inhibitors in the treatment of NSCLC patients with EGFR mutation，and explores improved treatment modalities for NSCLC patients with EGFR mutation.